Core Insights - Heartflow, Inc. announced significant findings from the FISH&CHIPS study, demonstrating that its FFRCT Analysis improves diagnostic decision-making and predicts cardiovascular events while providing substantial cost savings for healthcare systems [1][2][4] Group 1: Clinical Value - The FISH&CHIPS study, involving over 90,000 patients, is the largest FFRCT study to date, providing strong real-world evidence of the clinical benefits of Heartflow's technology [1][7] - Heartflow FFRCT Analysis predicts individual cardiovascular outcomes, including myocardial infarction (MI) and cardiovascular mortality, with lower FFRCT values correlating to higher risks of adverse events [3][5] - The technology enables clinicians to tailor care more precisely, improving patient outcomes and reducing costs [4][5] Group 2: Economic Impact - The introduction of Heartflow FFRCT Analysis into the NHS led to fewer avoidable tests and lower costs for both inpatient and outpatient care, resulting in significant savings for hospitals and patients [2][5] - The analysis indicated a per-patient cost saving of £1,042 GBP ($1,394 USD) over two years, suggesting potential annual savings of £25 million GBP ($33.45 million USD) for the health system [5] - Cost savings were observed from the first year and continued to persist in lifetime modeling, highlighting the economic viability of the technology [5] Group 3: Technological Advancements - Heartflow's platform integrates various analyses, including RoadMap™ Analysis and Plaque Analysis, enhancing the accuracy of CAD assessments [4][8] - The technology has been adopted by over 1,400 institutions globally, supported by extensive clinical validation and a large dataset of coronary imaging [8][9] - Heartflow's AI-driven solutions have been validated in over 100 studies, demonstrating high acceptance rates and reproducibility in clinical practice [8]

Core Insights - Heartflow, Inc. has received FDA 510(k) clearance for its Next Gen Heartflow Plaque Analysis algorithm, which is now available for use [1][2] - Cigna will cover Heartflow Plaque Analysis across all its lines of business starting in October 2025, following similar coverage by UnitedHealthcare [1][4] Technology Advancements - The Heartflow Plaque Analysis is the only FDA-cleared AI-powered plaque quantification tool, showing a 95% agreement with the gold standard, IVUS [2] - The new algorithm demonstrates a 21% improvement in plaque detection compared to the first-generation algorithm, enhancing clinician confidence in diagnosing CAD [2][3] - The updated platform features advanced 3D color-coded visualization of plaque type, volume, and distribution, providing clinicians with critical insights for care decisions [1][3][13] Clinical Impact - The enhanced nomogram is based on data from approximately 273,000 patients, which is nine times larger than any current plaque quantification study [3] - Heartflow Plaque Analysis has led to medical management changes in over 50% of patients beyond coronary CTA alone, with an expected event reduction of around 15% [5] Industry Position - Heartflow is recognized as a leader in coronary plaque analysis, with a commitment to transforming the management of coronary artery disease [5][6] - The company has supported nearly 500,000 patients worldwide, leveraging clinical rigor and a vast dataset of coronary CTA images [6]

Company Overview - Heartflow, Inc. is a leader in AI technology for coronary artery disease (CAD) [1] - The company is advancing coronary care by transforming CAD into a screenable, diagnosable, and manageable condition [3] - Heartflow One is the only complete, non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed CCTA pathway [3] - The AI-driven platform includes Roadmap™ Analysis, FFRCT Analysis, and Plaque Analysis, supported by the ACC/AHA Chest Pain Guideline and backed by over 600 peer-reviewed publications [3] - Heartflow has assisted clinicians in managing over 400,000 patients worldwide [3] Upcoming Events - Members of Heartflow management will participate in a fireside chat at the Morgan Stanley 23 Annual Global Healthcare Conference on September 10, 2025, at 6:15 a.m. PT / 9:15 a.m. ET [1] - A live and archived version of the fireside chat will be available on the Investor Relations section of the Heartflow website [2]

Core Points - Heartflow, Inc. has priced its upsized initial public offering (IPO) of 16,666,667 shares at $19.00 per share, aiming for gross proceeds of approximately $316.7 million before expenses [1] - The company has granted underwriters a 30-day option to purchase an additional 2,500,000 shares at the IPO price [1] - Trading on the Nasdaq Global Select Market is set to begin on August 8, 2025, under the ticker symbol "HTFL," with the offering closing expected on August 11, 2025 [1] Company Overview - Heartflow is focused on transforming coronary artery disease (CAD) into a screenable, diagnosable, and manageable condition through its AI-driven platform, Heartflow One [5] - The platform includes features such as Roadmap™ Analysis, FFRCT Analysis, and Plaque Analysis, and is supported by the ACC/AHA Chest Pain Guideline [5] - Heartflow has assisted clinicians in managing over 400,000 patients globally, backed by more than 600 peer-reviewed publications [5]